Webcast Wedbush PacGrow Healthcare Conference, August 13, 2019, 10:55 am ET, NY

Management team

Tim Van Hauwermeiren

MSc, EMBA
Chief Executive Officer

Read more

Tim Van Hauwermeiren

MSc, EMBA, Chief Executive Officer

Tim Van Hauwermeiren co-founded our company in 2008 and has served as our Chief Executive Officer since April 2008. He has served as a member of our board of directors since July 2014. Mr. Van Hauwermeiren has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Mr. Van Hauwermeiren holds a B.Sc. and M.Sc. in bioengineering from Ghent University (Belgium) and an Executive MBA from The Vlerick School of Management.

Keith Woods


Chief Operating Officer

Read more

Keith Woods

Chief Operating Officer

Keith Woods has over 25 years of experience in the biopharmaceutical industry. He most recently served as Senior Vice President of North American Operations for Alexion Pharmaceuticals Inc. (Alexion), where he managed a team of several hundred people in the U.S. and Canada and was responsible for more than $1 billion in annual sales. Within Alexion, he previously served as Vice President and Managing Director of Alexion UK, overseeing all aspects of Alexion’s U.K. business; Vice President of U.S. Operations; and Executive Director of Sales, leading the launch of Soliris in atypical hemolytic uremic syndrome. Prior to joining Alexion, he held various positions of increasing responsibility within Roche, Amgen and Eisai over a span of 20 years. Keith Woods holds a B.S. in Marketing from Florida State University.

Eric Castaldi


Chief Financial Officer

Read more

Eric Castaldi

Chief Financial Officer

Eric Castaldi has served as our Chief Financial Officer since April 2014 and as a member of our board of directors since July 2014. Mr. Castaldi will resign from our board of directors effective April 26, 2017. Mr. Castaldi has 28 years of international financial executive management experience, including 19 years in the biopharmaceutical industry. From 1998 to 2014, Mr. Castaldi served as chief financial officer and a member of the executive committee of Nicox SA, a Euronextlisted biotechnology company. From 2008 to 2012, he served as a member of the board of directors and as chairman of the audit committee of Hybrigenics Services SAS, a Euronext-listed French biopharmaceutical company specializing in oncology. Mr. Castaldi graduated with a degree in finance, accountancy and administration from the University of Nice.

Prof. Hans de Haard

PhD
Chief Scientific Officer

Read more

Prof. Hans de Haard

PhD, Chief Scientific Officer

Hans de Haard is a serial pioneer of antibody platforms and has been active in the antibody engineering field since 1989, initially at AKZO Nobel. Subsequently, at the University of Maastricht, he created a large non-immune human Fab library that subsequently became a core asset of Dyax, yielding multiple therapeutic antibodies including ImClone products IMC-A12, IMC-1F8 and the recently approved anti-VEGFR2 antibody ramucirumab (formerly called IMC-1121B). From 1998 to 2002 he was responsible for the discovery of llama VHH-based products at Unilever.

From 2002 until he joined argenx, Prof. de Haard worked at Ablynx NV as Director Technology Development, and latterly as Senior Director Discovery Research. He was responsible for setting up the Nanobody® discovery engine and introduced VHH formatting, which turned out to be a major advantage of this platform. He was centrally involved in the development of the Nanoclone® methodology based on B cell selection.

During his career, Prof. de Haard has discovered numerous therapeutic antibody leads, seven of which are now progressing in the clinic. He holds a Master of Science in Biochemistry and a PhD in Molecular Immunology from the University of Maastricht. He is a Professor of  Immunology at University of Franche Comté  (Besançon, France).

 
Dirk Beeusaert


General Counsel

Read more

Dirk Beeusaert

General Counsel

Dirk Beeusaert has served as our General Counsel since April 1, 2017. Mr. Beeusaert has extensive general experience in corporate governance and as general counsel of a listed company. Mr. Beeusaert worked in various roles from February 1996 to July 2016 for Gimv NV, a European private equity company listed on Euronext Brussels, most recently as the general counsel, where he was co-responsible for operations and corporate governance. Mr. Beeusaert currently serves as a member of the boards of directors of Pragma Capital SAS and Cubigo NV. Mr. Beeusaert holds a Bachelor in Law and a Master Law degree from Ghent University and an MBA in Fiscal Studies and Accounting Research, Tax and Accounting from Vlerick Leuven-Gent Management School

Wim Parys

MD
Chief Medical Officer

Read more

Wim Parys

MD, Chief Medical Officer

Wim Parys obtained a MD degree from the Katholieke Universiteit Leuven, Belgium.  He was in private practice for 9 years before joining the Janssen Research Foundation in Beerse, Belgium where he held several R&D positions and developed galantamine (Reminyl™ / Razadyne™) for Alzheimer’s Disease. 

In 2000 he became the Head of Development at the biotech company Tibotec and relocated to the US to establish Tibotec Inc., the US based subsidiary.  Under his tenure, Tibotec (then acquired by J&J) developed and launched Prezista™, Intelence™ and Edurant™, three innovative HIV drugs. 

As Development Head of Janssen’s Infectious Diseases and Vaccines therapeutic area, he lead the discovery and development of other medicines for HIV, Hepatitis C (Incivo™, Olysio™/Sovriad™), TB (Sirturo™) and respiratory viral diseases.        

In 2013 he became the R&D head of the newly established Global Public Health group, responsible for a portfolio including programs in HIV, TB, other mycobacterial infections, Dengue and Malaria.

Earl 2019, he joined argenx as a development consultant.

Arjen Lemmen

MSc
VP Corporate Development & Strategy

Read more

Arjen Lemmen

MSc, VP Corporate Development & Strategy

Arjen Lemmen serves as the head of our strategy and corporate development activities. He joined argenx in 2016 and has successfully executed several transactions including a number of programs within our Innovative Access Program and our strategic collaboration with Janssen on cusatuzumab. Prior to joining argenx, he served as a corporate finance specialist at Kempen & Co focusing on M&A, Equity Capital Markets and strategic advisory transactions in the European life sciences industry. Mr. Lemmen holds a B.Sc. in Life Science & Technology from the University of Groningen (the Netherlands) and Master of Engineering Management from Duke University.